Matthew J Baggott1, Matthew G Kirkpatrick2, Gillinder Bedi3, Harriet de Wit4. 1. Department of Psychiatry and Behavioral Neurosciences, University of Chicago, Chicago, IL, USA. 2. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA. 3. Department of Psychiatry, Columbia University, New York, NY, USA. 4. Department of Psychiatry and Behavioral Neurosciences, University of Chicago, Chicago, IL, USA hdew@uchicago.edu.
Abstract
RATIONALE: ±3,4-methylenedioxymethamphetamine (MDMA) is widely believed to increase sociability. The drug alters speech production and fluency, and may influence speech content. Here, we investigated the effect of MDMA on speech content, which may reveal how this drug affects social interactions. METHOD: Thirty-five healthy volunteers with prior MDMA experience completed this two-session, within-subjects, double-blind study during which they received 1.5 mg/kg oral MDMA and placebo. Participants completed a five-minute standardized talking task during which they discussed a close personal relationship (e.g. a friend or family member) with a research assistant. The conversations were analyzed for selected content categories (e.g. words pertaining to affect, social interaction, and cognition), using both a standard dictionary method (Pennebaker's Linguistic Inquiry and Word Count: LIWC) and a machine learning method using random forest classifiers. RESULTS: Both analytic methods revealed that MDMA altered speech content relative to placebo. Using LIWC scores, the drug increased use of social and sexual words, consistent with reports that MDMA increases willingness to disclose. Using the machine learning algorithm, we found that MDMA increased use of social words and words relating to both positive and negative emotions. CONCLUSIONS: These findings are consistent with reports that MDMA acutely alters speech content, specifically increasing emotional and social content during a brief semistructured dyadic interaction. Studying effects of psychoactive drugs on speech content may offer new insights into drug effects on mental states, and on emotional and psychosocial interaction.
RCT Entities:
RATIONALE: ±3,4-methylenedioxymethamphetamine (MDMA) is widely believed to increase sociability. The drug alters speech production and fluency, and may influence speech content. Here, we investigated the effect of MDMA on speech content, which may reveal how this drug affects social interactions. METHOD: Thirty-five healthy volunteers with prior MDMA experience completed this two-session, within-subjects, double-blind study during which they received 1.5 mg/kg oral MDMA and placebo. Participants completed a five-minute standardized talking task during which they discussed a close personal relationship (e.g. a friend or family member) with a research assistant. The conversations were analyzed for selected content categories (e.g. words pertaining to affect, social interaction, and cognition), using both a standard dictionary method (Pennebaker's Linguistic Inquiry and Word Count: LIWC) and a machine learning method using random forest classifiers. RESULTS: Both analytic methods revealed that MDMA altered speech content relative to placebo. Using LIWC scores, the drug increased use of social and sexual words, consistent with reports that MDMA increases willingness to disclose. Using the machine learning algorithm, we found that MDMA increased use of social words and words relating to both positive and negative emotions. CONCLUSIONS: These findings are consistent with reports that MDMA acutely alters speech content, specifically increasing emotional and social content during a brief semistructured dyadic interaction. Studying effects of psychoactive drugs on speech content may offer new insights into drug effects on mental states, and on emotional and psychosocial interaction.
Authors: Matthew G Kirkpatrick; Royce Lee; Margaret C Wardle; Suma Jacob; Harriet de Wit Journal: Neuropsychopharmacology Date: 2014-01-22 Impact factor: 7.853
Authors: Jacqui Rodgers; Tom Buchanan; Carol Pearson; Andy C Parrott; J Ling; T M Hefferman; A B Scholey Journal: J Psychopharmacol Date: 2005-09-20 Impact factor: 4.153
Authors: Matthew G Kirkpatrick; Erik W Gunderson; Audrey Y Perez; Margaret Haney; Richard W Foltin; Carl L Hart Journal: Psychopharmacology (Berl) Date: 2011-06-30 Impact factor: 4.530
Authors: Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Scott F Martin; Berra Yazar-Klosinski; Yvonne Michel; Timothy D Brewerton; Rick Doblin Journal: J Psychopharmacol Date: 2012-11-20 Impact factor: 4.153
Authors: Christophe Lemey; Aziliz Le Glaz; Yannis Haralambous; Deok-Hee Kim-Dufor; Philippe Lenca; Romain Billot; Taylor C Ryan; Jonathan Marsh; Jordan DeVylder; Michel Walter; Sofian Berrouiguet Journal: J Med Internet Res Date: 2021-05-04 Impact factor: 5.428
Authors: Marcela Ot'alora G; Jim Grigsby; Bruce Poulter; Joseph W Van Derveer; Sara Gael Giron; Lisa Jerome; Allison A Feduccia; Scott Hamilton; Berra Yazar-Klosinski; Amy Emerson; Michael C Mithoefer; Rick Doblin Journal: J Psychopharmacol Date: 2018-10-29 Impact factor: 4.153
Authors: Carla Agurto; Guillermo A Cecchi; Raquel Norel; Rachel Ostrand; Matthew Kirkpatrick; Matthew J Baggott; Margaret C Wardle; Harriet de Wit; Gillinder Bedi Journal: Neuropsychopharmacology Date: 2020-01-24 Impact factor: 7.853